Prima BioMed replaces director


By Dylan Bushell-Embling
Thursday, 13 February, 2014

Prima BioMed (ASX:PRR) has added former investment banker Pete Meyers to its board as a non-executive director.

Meyers is currently CFO of TetraLogic Pharmaceuticals, where he led the execution of its IPO in December.

Before joining TetraLogic, Meyers was an investment banker. Notable roles in the industry include co-head of global healthcare investment banking at Deutsche Bank in New York. He also held various roles at Dillon, Read & Co and Credit Suisse First Boston.

“I believe Pete’s depth of experience in the US capital markets, his network in the biotech community and his expertise advising healthcare companies will serve Prima well,” Prima Chairperson Lucy Turnbull said.

Meyers will be replacing Dr Richard Hammel, who is stepping down from the board after serving since January 2005.

Prima BioMed (ASX:PRR) shares were trading 4.08% higher at $0.051 as of around 2 pm on Tuesday.

Related News

Research project to produce fish-free omega-3

SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...

Biodegradable smart patch can detect and treat blood clots

Researchers have developed a biodegradable smart patch that detects pressure changes and releases...

Biotech manufacturing facility opens in Brisbane

ENTRI, a purpose-built multimodal facility which will enable biotech companies to manufacture...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd